Absence of Mortality Differences Between the First and Second COVID-19 Waves in Kidney Transplant Recipients

This article has been Reviewed by the following groups

Read the full article

Abstract

No abstract available

Article activity feed

  1. SciScore for 10.1101/2021.12.15.21267794: (What is this?)

    Please note, not all rigor criteria are appropriate for all manuscripts.

    Table 1: Rigor

    EthicsIRB: This prospective registry was approved by the Institutional Review Board of Strasbourg University (approval number 02.26) and registered at clinicaltrials.gov (NCT04360707).
    Consent: Of note, all patients were informed about their inclusion in the registry but the need for informed consent was waived.
    Sex as a biological variablenot detected.
    Randomizationnot detected.
    Blindingnot detected.
    Power Analysisnot detected.

    Table 2: Resources

    No key resources detected.


    Results from OddPub: We did not detect open data. We also did not detect open code. Researchers are encouraged to share open data when possible (see Nature blog).


    Results from LimitationRecognizer: We detected the following sentences addressing limitations in the study:
    Our study has however also some limitations. First, we compared two periods (first and second wave) but did not take into account COVID-19 ICU occupancy rates, a factor thought to impact on mortality rates13. Second, our study was not designed to capture the impact of vaccines, which only became available early 2021. Accumulating evidence suggests however that KTR have an impaired response to the “standard” 2-dose of mRNA vaccine44–47, which leaves them at high risk of severe COVID-1946,48. Despite intensified scheme of vaccination (with third and even a fourth vaccine dose now recommended in weak responders), up to 20% of KTR will not develop sufficient protection against COVID-1949–51. In this regard, the development of monoclonal neutralizing anti-SARS-CoV-2 Spike Protein Antibodies represent an interesting therapeutic option. The latter are already available in high-risk patients diagnosed with mild to moderate COVID-1952 (post-exposition therapy) and first reports about their use for prophylaxis (pre-exposition therapy) are promising53. In conclusion, changing of therapeutic trends during 2020 did not reduce COVID-19 related mortality in KTR. Our data thus indirectly stress the importance of therapeutic progresses made during 2021, including vaccination and monoclonal neutralizing anti-SARS-CoV-2 spike protein antibodies, to protect this vulnerable population from death due to COVID-19.

    Results from TrialIdentifier: We found the following clinical trial numbers in your paper:

    IdentifierStatusTitle
    NCT04360707RecruitingSolid Organ Transplant Recipients With SARS-CoV-2 French Reg…


    Results from Barzooka: We did not find any issues relating to the usage of bar graphs.


    Results from JetFighter: We did not find any issues relating to colormaps.


    Results from rtransparent:
    • Thank you for including a conflict of interest statement. Authors are encouraged to include this statement when submitting to a journal.
    • Thank you for including a funding statement. Authors are encouraged to include this statement when submitting to a journal.
    • No protocol registration statement was detected.

    Results from scite Reference Check: We found no unreliable references.


    About SciScore

    SciScore is an automated tool that is designed to assist expert reviewers by finding and presenting formulaic information scattered throughout a paper in a standard, easy to digest format. SciScore checks for the presence and correctness of RRIDs (research resource identifiers), and for rigor criteria such as sex and investigator blinding. For details on the theoretical underpinning of rigor criteria and the tools shown here, including references cited, please follow this link.